The Pharmacological Effects of Phenylephrine are Indirect, Mediated by Noradrenaline Release from the Cytoplasm

Mahmoud Al-Khrasani1 · David A. Karadi1 · Anna R. Galambos1 · Beata Sperlagh2 · E. Sylvester Vizi1,2

Received: 5 May 2022 / Revised: 4 July 2022 / Accepted: 6 July 2022 / Published online: 9 August 2022
© The Author(s) 2022

Abstract
Phenylephrine (PE) is a canonical α1-adrenoceptor-selective agonist. However, unexpected effects of PE have been observed in preclinical and clinical studies, that cannot be easily explained by its actions on α1-adrenoceptors. The probability of the involvement of α2- and β-adrenoceptors in the effect of PE has been raised. In addition, our earlier study observed that PE released noradrenaline (NA) in a [Ca2+]o-independent manner. To elucidate this issue, we have investigated the effects of PE on [3H]NA release and α1-mediated smooth muscle contractions in the mouse vas deferens (MVD) as ex vivo preparation. The release experiments were designed to assess the effects of PE at the presynaptic terminal, whereas smooth muscle isometric contractions in response to electrical field stimulation were used to measure PE effect postsynaptically. Our results show that PE at concentrations between 0.3 and 30 µM significantly enhanced the resting release of [3H]NA in a [Ca2+]o-independent manner. In addition, prazosin did not affect the release of NA evoked by PE. On the contrary, PE-evoked smooth muscle contractions were inhibited by prazosin administration indicating the α1-adrenoceptor-mediated effect. When the function of the NA transporter (NAT) was attenuated with nisoxetine, PE failed to release NA and the contractions were reduced by approximately 88%. The remaining part proved to be prazosin-sensitive. The present work supports the substantial indirect effect of PE which relays on the cytoplasmic release of NA, which might explain the reported side effects for PE.

Keywords Phenylephrine · Indirect action · Noradrenaline transporter · Noradrenaline release · α1-Adrenoceptor · Cytoplasmic origin

Introduction
The binding of drugs to receptors is a necessary step in the production of molecular and cellular responses. Since Ahlquist’s discovery [1] that receptors that are sensitive to noradrenaline (NA) may be classified as α- or β-receptors, several studies have provided convincing evidence that α-adrenoceptors may be further divided into subtypes of α1 and α2. Further developments in pharmacology and molecular biology revealed additional heterogeneity and the existence of six α- and three β-adrenoceptors. Pharmacological and radioligand binding assays of α1 receptors expressed in native cells identified three subtypes [2]. Molecular biological studies have provided convincing evidence that there are three genes encoding α1aa, α1ab and α1ad-adrenoceptors that correspond to the α1A-, α1B- and α1D-receptors [3]. Several reviews have discussed α1-adrenoceptor agonists [3, 4], and textbook chapters focused on these agonists, such as Goodman and Gilman and Rang and Dale’s Pharmacology [5, 6], in which phenylephrine (PE) was canonised as a primary and directly-acting drug on α1-adrenoceptors. This classification was supported by the potency and intrinsic activity of PE on recombinant α1A receptors [7, 8]. This subtype is involved in NA-induced vasoconstriction which leads to increased blood pressure and contraction of the longitudinal muscle in the vas deferens and lower urinary tract via stimulation [9].

Phenylephrine (PE), a direct-acting α1-adrenoceptor agonist, is primarily used clinically as a vasopressor of choice to prevent spinal anaesthesia-induced hypotension in healthy parturients undergoing caesarean delivery [10] and in the treatment of hypotension in surgical patients.
and patients with septic shock. PE is also widely used as a nasal decongestant and mydriatic agent.

However, certain unexpected observations have been reported in preclinical studies of PE, including α2-adrenoceptor-mediated presynaptic inhibitory actions on the release of NA [11–13] and acetylcholine [14]. Flavahan and McGrath [15] demonstrated simultaneous α1, α2, β1 and β2 adrenoceptor-mediated effects of PE in the cardiovascular system of pithed rats. β-receptor-mediated positive inotropic and chronotropic effects of PE were observed in atria isolated from guinea pigs and rabbits, while methoxamine did not exhibit these effects [16]. Similarly to guinea pig, in rat papillary muscles, the positive inotropic and chronotropic effects of PE were effective inotropic responses to PE were unaffected by the α1 receptor activation [13], which is a characteristic target of NA.

Similar unexpected observations were also found in human experiments and clinical practice, such as PE production of a β-adrenoceptor-mediated action in the human forearm [18]. β-receptor-mediated immunosuppression in response to PE infusion was recently shown in humans, specifically, enhanced IL-10 and reduced proinflammatory cytokine production [19], which compromised host defence and increased susceptibility to infection. Adverse effects, including an increased heart rate, a typical β-adrenoceptor action and decreased blood pressure, have been reported even after eye-drop applications in a meta-analysis [20].

The release of NA in response to PE has been consistently observed, but the contribution of the indirect component of PE to the pharmacological effect was deemed negligible [11, 21] or claimed as an effect of α1-adrenoceptor that was distinct from the effects in other organs [22]. Other studies provided convincing neurochemical evidence that PE [23], in contrast to methoxamine and (−)-amidiphine [24], released NA in a [Ca2+]i-independent manner in vas deferens isolated from mice. Due to the canonical interpretation in the literature and the consequence of the prominence of textbook data that PE is a direct-acting α1-agonist, the authors neglected to discuss or prove that the NA released by PE might also be involved in its effects on smooth muscle. MVD is well-known to host different types of α-adrenoceptors located both on presynaptic membrane and smooth muscle [25, 26].

The present study provides the first neurochemical and functional evidence that the release of a considerable amount of NA in response to various concentrations of PE is prevented, and the contractile effects (fast and slow) on smooth muscle cells are also substantially attenuated by the inhibition of NAT.

Methods

Animals

Male NMRI mice (35–45 g) were purchased from Toxicoop Zrt. (Budapest, Hungary) and their vas deferens was used for recording contractions. Male CD1 mice weighing 28–45 g were obtained from Charles River (Budapest, Hungary) and housed in a local animal facility and used for release experiments. Animals were kept in groups in a temperature- and humidity-controlled room under a 12-h light/dark cycle and under standard conditions of laboratory animal housing. The experiments followed the guidelines of the Ethical Board of Semmelweis University (EC Directive 2010/63/EU). The Semmelweis University Regional and the Institutional Committee of Science and Research Ethics committees approved the experimental protocol (PE/EA/285-5/2020). Food and water were available ad libitum. The animals were slightly anaesthetised before the tissue preparations.

Isolated Mouse Vas Deferens

Experiments on smooth muscle contraction were performed as previously described with slight modifications [27]. Briefly, vasa deferentia were removed from the mice, desheathed and suspended between an upper (ring) and a lower (straight) electrode in 5 ml organ baths containing Krebs solution (concentrations in mM: NaCl, 118.0; NaHCO3, 25.0; KCl, 4.7; KH2PO4, 1.2; glucose, 11.0; CaCl2, 2.5; and MgSO4, 1.2) aerated with a gas mixture of 95% O2 and 5% CO2. The upper end of the isolated organ was attached to a transducer using a thread and connected to a computer via an amplifier. The resting tension was adjusted to 0.1 g. Electrical field stimulation was applied. The parameters of the stimulation included trains (10 Hz with 20 rectangular impulses at a 1-ms pulse width, 9 V/cm; i.e., supramaximal intensity) repeated with 0.1 Hz (Stimulator 88, Grass Medical Instruments, Quincy, MA, USA).

Experimental Paradigms

In experiments designed to assess the effects of test compounds in MVD muscle contractions, vasa deferentia were equilibrated under electrical stimulation for 20–30 min before drug administration. Next, electrical stimulation was stopped, and PE or NA was administered at different concentrations and left for 2 min before washing. Electrical stimulation was initiated again, and nisoxetine or prazosin was added to the organ bath and left for 15–20 min to equilibrate before adding PE or NA again without electrical stimulation. The temperature of the Krebs solution was kept constant.
using a thermoelectric device (Frigomix 2000, B. Braun, Germany). Similar protocol was followed when the effect of PE was determined in MVD from mice treated with reserpine or vehicle (5 mg/kg, i.p., 18 h) prior to the experiments.

**Release of [3H]Noradrenaline**

The release of [3H]NA was measured using ex vivo preparations from the MVD. The experiments were performed in strict accordance with the European Directive (2010/63/EU) and the institutional guidelines. Mice were anaesthetised and decapitated. The vasa deferentia were quickly removed and placed in ice-cold Krebs solution. Release experiments were performed as previously described [23]. Briefly, small pieces of the preparations were incubated in 1 ml of Krebs solution containing 5 µCi/ml [3H]NA for 45 min. After incubation, the preparations were transferred to micro tissue chambers and continuously perfused with Krebs solution at a rate of 0.5 ml/min. After 45 min of perfusion, samples were collected every 3 min and assayed for radioactivity. During the release experiments, Krebs solution contained 10 µM paraglyine in order to inhibit the production of NA metabolites [28]. The total radioactivity released from the tissue and collected in the superfusate was accepted as the amount of [3H]NA released [29] [30]. In our earlier study the release of NA in response to PE was [Ca2+]o-independent, which suggests a neuronal and vesicular origin of the release [31]. In contrast, the release was of cytoplasmic origin under resting conditions. In the vas deferens preparations the release of NA in response to PE was [Ca2+]o-independent in our experiments. For experiments in which calcium was removed, 1 mM EGTA was added to the Krebs solution, and the tissue was exposed to this modified Krebs solution throughout the experiments.

In a distinct set of experiments, mice were pre-treated with reserpine (5 mg/kg, i.p., 18 h) prior to the experiments. Unless otherwise indicated, all experiments were performed at 37 °C in Krebs solution (pH 7.4). The same conditions were used during the recording of smooth muscle contractions, and the solution was continuously saturated with 95% O₂ and 5% CO₂.

**Reagents**

Levo-[7-3H]-noradrenaline (specific activity = 20 Ci/mmol) was purchased from American Radio-labeled Chemicals (St. Louis, MO, USA). The following drugs were used: prazosin HCl (RBI), reserpine (Tocris Bioscience, Bristol, UK) nisoxetine HCl and cocaine HCl (Sigma-Aldrich, Budapest, Hungary). All other chemicals were obtained from Sigma-Aldrich (Budapest, Hungary).

**Data Analysis**

In case of all the quantifications and data analysis, the analyst was blind to the origin of the data during statistical analysis. All the group data subjected to statistical analysis had a minimum of n = 5 of independent values per group. Group sizes are shown in each figure. Statistical analyses were performed using GraphPad Prism 8.01 software (San Diego, CA, USA). Normality was tested by Shapiro–Wilk test and based on the result, parametric or nonparametric tests were used. In contraction experiments with isolated mouse vas deferens, the area under the curve (AUC) values of the 2 min time period following PE or NA administration were calculated as the integral of the contraction curve relative to the baseline. When multiple comparisons were necessary, one-way ANOVA followed by Tukey’s post hoc test was used. Post hoc tests were run only if F achieved p < 0.05. Significant differences between two groups were analysed using two-tailed paired t-test. p < 0.05 was considered as statistically significant.
**Results**

**Effects of Field Stimulation and Phenylephrine on Contractions and [3H]NA Release from the Vas Deferens**

Consistent with previous studies [32, 33], a biphasic contractile response of the vas deferens to trains of electrical field stimulation was observed. PE produced a fast contraction, followed by the maintenance of smooth muscle contraction, in a concentration-dependent manner. Figure 1 shows that prazosin inhibited field stimulation and PE-induced contractions (Fig. 1A, C). The AUC values for the PE-induced contractions are shown in the presence of the postsynaptic α₁-antagonist prazosin and vehicle (Fig. 1C).

In experiments designed to determine the effect of stimulation on the release of NA, after the preparations were loaded with [3H]NA, the average uptake of radioactivity was 1,001,280 ± 47,956 Bq/g (n = 24), and the average resting release during a 3-min collection period (FRR₁) was 1.10 ± 0.11% of the total radioactivity (n = 8). Resting release was maintained: the FRR₂/FRR₁ was 0.94 ± 0.08 (n = 6) after 21 min elapsed between the two measurements. FRR₁ was used as the internal standard. Electrical stimulation (10 Hz, 20 shocks) significantly enhanced the release of radioactivity at the top of the resting release (S₁ = 61,553 ± 9724 Bq/g or 1.70 ± 0.25% of the total radioactivity) (n = 8, p < 0.05).

When the preparations were loaded with [3H]NA in parallel experiments the uptake of radioactivity was significantly lower in tissues in which 3 μM PE was added to the loading Krebs solution (755,000 ± 45,000 vs. 124,000 ± 43,000 Bq/g, p < 0.05, n = 6–6). This effect of PE is due to its substrate activity preventing [3H]NA for uptake by NAT.

PE increased the resting release of [3H]NA in a concentration-dependent manner (Fig. 2A). The release was maintained as long as the tissue was exposed to PE. In fact, PE still significantly increased the release at concentrations as low as 0.3 μM (FRR₂/FRR₁ = 1.19 ± 0.07 (n = 6, p < 0.05) (Fig. 2A), and 0.8 μM PE was required to double the concentrations of NA (Fig. 2B) in the extracellular space.

Although prazosin failed to affect PE-induced NA release (Fig. 3A), it inhibited both fast and slow PE-evoked contractions (Fig. 1A, C) which indicated the role of α₁-adrenoceptors in smooth muscle contractions. Similar to our earlier findings [4], the PE-evoked release was [Ca²⁺]₀-independent (Fig. 3B), which indicated that the release was not vesicular in nature.

![Fig. 1](image)

**Fig. 1** Effect of prazosin (10 μM) on electrical field stimulation or PE-induced contractions in isolated mouse vas deferens. Contractions induced by PE on mouse vas deferens in the presence of prazosin (A) versus vehicle (B). The organs were allowed to equilibrate under electrical stimulation (trains of 10 Hz with 20 shocks were delivered at 0.1 Hz) for 20–30 min before PE administration. Next, the organ bath was washed out, and the organs were equilibrated once more in the presence of prazosin for 15–20 min. The effect of PE is presented as AUC values (C), which were calculated as the integral of the contraction curve relative to the baseline of the 2 min period for each contraction. The AUC values are presented as the mean ± S.E.M. (C). *: significant difference versus control. Gaussian distribution was assumed following ns. Shapiro–Wilk test (alpha=0.05). The significance levels were determined by one-way ANOVA followed by Tukey’s post hoc test.
Evidence of Cytoplasmic Release of NA in Response to Phenylephrine via the Transporter, Effects of Nisoxetine and Cocaine

Monoamine transporters play a pivotal role in altering the concentrations of monoamines in the extracellular space surrounding the axon terminals via an uptake mechanism. Nisoxetine is a selective inhibitor of NATs that prevents the reuptake of NA and increases the extraneuronal concentration of NA once released. Therefore, we studied the effect of PE when NAT was inhibited to identify the mode of action. Nisoxetine (10 µM) substantially inhibited PE from eliciting smooth muscle contraction (Fig. 4A, B, D) and completely prevented PE-induced NA release (Fig. 4E), supporting the critical role of NAT in this effect. PE (3 µM) produced contractions of AUC values of 10.17 ± 1.21 and 3.91 ± 0.65 or 0.86 ± 0.23 in the presence of 10 µM or 30 µM nisoxetine, respectively (Fig. 4D). Furthermore, nisoxetine failed to fully inhibit PE-evoked contractions, even at concentrations as high as 100 µM (Fig. 4D). This indicates that, at higher concentrations nisoxetine showed a ceiling effect in inhibiting the contractions. The finding that when NA release was inhibited by nisoxetine, the contractions that remained (~ 12% of the control) could be inhibited by prazosin, may represent the direct effect of PE on α1-adrenoceptors expressed on smooth muscle. The vehicle failed to affect PE-evoked contractions (Fig. 4C, D). Nisoxetine did not affect NA-induced smooth muscle contractions, which excluded its postsynaptic effects (Fig. 5). Cocaine is a nonselective monoamine transporter inhibitor that also significantly attenuated the release of NA in response to PE (Fig. 6).

Effects of Phenylephrine on Contractions of the Vas Deferens When the Vesicular Storage of NA is Impaired

Vesicular monoamine transport (VMAT2) regulates the storage and exocytotic release of monoamines [34].
Reserpine binds to vesicular transporters irreversibly [35] and prevents cytoplasmic NA from being stored in vesicles. Therefore, reserpine pre-treatment (5 mg/kg i.p. 18 h) was used to reduce or exclude the possible role of exocytotic NA in the effects of PE on contractions. Under the condition when the vesicular origin of NA was reduced or ruled out and reuptake of NA from the extracellular space was inhibited the responses to PE were potentiated in a prazosin-inhibition susceptible manner (Table 1). When vesicular storage of NA was impaired by reserpine-pre-treatment, and the NAT was inhibited by nisoxetine concomitantly, PE always retained some intrinsic activity in a concentration-dependent manner (Fig. 7). Consistent with these findings, reserpine pre-treatment failed to prevent the positive inotropic effect of PE [22], and the responses of vas deferens to NA and methoxamine were potentiated 25-fold and fivefold, respectively, after 6-hydroxydopamine treatment [36] and surgical denervation [37].

The Release of [3H]Noradrenaline from Preparations Following Reserpine Pretreatment

The release of [3H]NA was measured in vas deferens tissue prepared from animals untreated and pre-treated with reserpine in parallel experiments. While the uptake of [3H]NA was significantly lower in preparations dissected from reserpine-treated (5 mg/kg i.p. 18 h) than in controls (118,000 ± 8,620 Bq/g treated vs. 784,500 ± 30,608 Bq/g in the control, p < 0.05, n = 5–5) the resting release was significantly higher in these preparations (Fig. 8). PE produced a transient increase (Fig. 8). Although PE failed to exert its excessive effect on NA release to the same extent as in the control preparations, it still produced prazosin inhibitable contractions of a larger magnitude than the control experiments (Table 1). Spontaneously active contractions of the smooth muscle in reserpine treated preparations observed in few experiments are attributable to low NA content [37],

### Fig. 3
Prazosin failed to affect the PE-induced release of [3H]NA (A), the effect of PE is external calcium independent (B). The release was measured as described in Methods. Prazosin was added into the Krebs solution from the 6th fraction and kept in the solution throughout the experiment. PE was added from the 8th fraction. Values are presented as mean ± S.E.M. *: significant difference between groups. Gaussian distribution was assumed following ns. Shapiro–Wilk test (alpha = 0.05). The significance levels were determined by one-way ANOVA followed by Tukey’s post hoc test.
the high spontaneous resting release of NA (Fig. 7) and the supersensitivity of the smooth muscle to NA (Table. 1).

**Discussion**

PE has been reported to exhibit unexpected pharmacological effects in preclinical studies [12, 15–17] and clinical treatments [18–20], which are characteristic of α2- and β-adrenoceptor stimulation. These actions are not easily explained by a direct α1-adrenoceptor-mediated response to PE, a drug very frequently used in medical practice, which was shown and concluded in the studies published with several recombinant and native assays [2, 38–40] as typically representative of α1-agonists. Accordingly, PE is classified [3] as a purely directly-acting sympathomimetic in the overwhelming majority of publications [41, 42] and textbooks.

The textbook classification of PE does not exclude the possibility that a directly-acting α1-agonist is able to release NA stored in axon terminals. This indicates that this release does not contribute to the response of effective cells. However, our data, suggest that this is not the case.

Our earlier study obtained neurochemical evidence, which indicated that the selective α1-adrenoceptor agonist PE [4, 23], but not methoxamine or (−)-amidephrine [4], both are accepted as α1-agonists, released NA from isolated vas deferens preparations in a [Ca²⁺]₀-independent way.

The present study used one of the most useful ex vivo preparations for studying noradrenergic neurochemical transmission, isolated vas deferens, and showed that PE acts indirectly and its action is attributable to its NA-releasing capacity. Consistent with our earlier observations, PE released NA in a concentration-dependent manner (Fig. 2). The effect of PE on NA release is [Ca²⁺]₀-independent
Neurochemical Research (2022) 47:3272–3284

The effect of nisoxetine on the contractions evoked by NA in isolated MVD

Fig. 5 Effect of nisoxetine (10 μM) on NA-induced contractions in isolated mouse vas deferens. The effect of noradrenaline is presented as AUC values which were calculated as the integral of the contraction curve relative to the baseline of the 2 min period for each contraction. The AUC values are presented as the mean ± S.E.M., p=0.7602 (ns). The significance level was determined by two-tailed paired t-test.

[4] (Fig. 3B), which suggests that the release of NA is of non-vesicular origin. It is known that under physiological conditions, transmitters stored in vesicles are released in response to action potentials after extraneuronal Ca²⁺ enters the nerve terminals, but Ca²⁺-independent release at rest is non-exocytotic, due to the reversal of the transporter [43]. Monoamines (NA, dopamine, and serotonin), phenylethylamine [44], and amphetamines [45] are translocated by transporters through the plasma membrane, which results in an efflux of transmitters residing in the cytoplasm.

PE is also known to be the substrate of the uptake mechanism [48] and the reverse mode of transporter function produced by extraneuronal substrates can be prevented by the inhibition of transporters [45]. Indeed, nisoxetine, a selective NAT inhibitor impeding translocation of the substrate prevented both PE-induced NA release (Fig. 4E) and substantially attenuated smooth muscle contractions (Fig. 4A, B, D), and did not influence the contractile effect of exogenous NA on smooth muscle (Fig. 5). Meanwhile cocaine, a nonselective transporter inhibitor, also reduced PE-induced NA release (Fig. 6), strongly indicating role of NAT in the α₁-adrenoceptor activity of PE. These results provide convincing evidence that the contractile effect of PE on smooth muscle was due to NA released from noradrenergic axon terminals and that NAT played a critical role in the cytoplasmic release of NA, an effect mediated via transporter reversal independently on axonal activity and represents an analog type of signal transmission described in the central nervous system [44]. The distinct role of the substrate property of PE in its indirect effects is supported by the fact that methoxamine, an α₁-adrenoceptor agonist but unlike PE, is not a substrate of NAT [48] and does not release NA [49].

The role of ATP released from the nerve terminals [29, 50, 51] in sympathetic transmission, specifically in contracting visceral and vascular smooth muscles, is widely accepted [33]. Furthermore, the observations of Westfall et al. [52] that ARL 67156, an ecto-ATPase inhibitor enhanced the responses of the vas deferens to various activations also indicate the possible involvement of ATP. The fact that ATP

Resting and PE-induced [3H]NA release in the presence of cocaine

Fig. 6 The resting release of [3H]NA induced by 10 μM PE in mouse vas deferens preparation in the presence or absence of 10 μM cocaine. The release was measured as described in Methods. The preparation was stimulated with supramaximal voltage (10 Hz, 20 shocks) at third fraction. Cocaine was added into the Krebs solution from the 6th fraction and kept in the solution throughout the experiment. PE was added from the 8th fraction. For calculations of FRR1 and FRR2 see Methods. Statistical analysis was made using two-way ANOVA followed by Tukey’s post-hoc test, the analysis was made between fractions 10–19, n=6 for each group.

 Springer
Table 1 The effect of pre-treatment with or without reserpine on PE or NA-induced contractions in isolated mouse vas deferens

| Treatment                  | AUC ± SEM (g) |
|----------------------------|---------------|
|                           | PE (3 µM)     | NA (3 µM)     |
| No pre-treatment with reserpine |               |               |
| Control^                  | 11.35 ± 0.94  | 9.46 ± 1.33   |
| Pre-treatment with reserpine |               |               |
| Control^                  | 20.22 ± 1.35^b (n = 9) | 19.74 ± 1.79^b (n = 9) |
| Prazosin 10 µM            | 0.073 ± 0.018^c (n = 6) | N.D          |
| Control^                  | 21.27 ± 2.77 (n = 6) | N.D          |
| Nisoxetine 10 µM          | 12.39 ± 2.74^c (n = 6) | N.D          |
| Control^                  | 18.04 ± 4.29 (n = 6) | N.D          |
| Nisoxetine 30 µM          | 6.91 ± 1.69^c (n = 6) | N.D          |

The effect of 10 µM prazosin, 10 µM nisoxetine or 30 µM nisoxetine on PE-induced smooth muscle contractions. The organs were obtained from reserpine or no treatment (5 mg/kg ip.; 18 h prior to the experiment) animals. These preparations were allowed to equilibrate under electrical stimulation (trains of 10 Hz with 20 shocks were delivered) for 20–30 min prior to PE administration. Next, the organ bath was washed out, and the organs were equilibrated once more in the presence of prazosin or nisoxetine for 15–20 min. The effect of PE or NA is presented as AUC values which were calculated as the integral of the contraction curve relative to baseline of the 2 min period for each contraction. The AUC values are presented as the mean ± S.E.M

^a Obtained from the first contraction induced by PE or NA

^b Significant difference versus vehicle pre-treated

^c Significant difference versus control. Gaussian distribution was assumed following ns. Shapiro–Wilk test (alpha = 0.05). The significance levels were determined by one-way ANOVA followed by Tukey’s post hoc test in the experiments assessing the effect of reserpine treatment on the contractions induced by PE or NA. Whereas, two-tailed, paired t-test was used in the experiments with prazosin or nisoxetine

Fig. 7 Representative figure of the concentration-dependent contractile effect of PE on smooth muscle under condition in which both vesicular and PE-induced transporter-mediated release of NA are impaired by reserpine pre-treatment and nisoxetine, respectively. The reuptake of NA is also inhibited by nisoxetine contributing to loss of releasable content of vesicles. Reserpinized mouse vas deferens (5 mg/kg i.p. 18 h). Note, the size of contractions induced by train (10 Hz, 20 shocks) at 0.1 Hz reduces by time and PE is still able to contract smooth muscle in a concentration-dependent manner. Take into account that smooth muscles to NA and PE (see Table 1) are supersensitive

and NA are co-stored in synaptic vesicles [53] [54] and are co-released from sympathetic nerve terminals in response to axonal stimulation [55] supports the role of presynaptic ATP. Nevertheless, the contractile effect of PE is due to the non-vesicular and [Ca^{2+}]_i-independent release of NA (Fig. 3B) from the cytoplasm, which may indicate that the role of ATP of presynaptic origin in the effect of PE can be ruled out. Whereas, the role of postsynaptic ATP released in response to α1-adrenoceptor activation by NA [31] remains to be studied.

Given the fact that under conditions in which vesicular release, due to reserpine-pre-treatment, or cytoplasmic
origin of NA by nisoxetine, were excluded, PE always retained some intrinsic activity in a concentration-dependent manner (Fig. 7) and contracted smooth muscle in a prazosin-inhibitable manner (Table 1) indicates that this effect of PE might have been mediated directly via \( \alpha_1 \)-receptors and could have been estimated in binding studies with recombinant methods.

The interaction between PE and NAT described in the present paper, in which NAT in operation is eo ipso needed for PE to be able to release NA raises a clinically important question. As far as the future clinical practice is concerned, taking into account our observations that PE, the substrate of transporters inhibited NAT function, brings attention to the possibility of interactions. In patients who are undergoing surgery and have been chronically treated with tricyclic antidepressants, the application of PE to prevent hypotension during spinal anaesthesia may be less effective because the release of NA due to impairment of NAT function is prevented. This interaction seems to be similar to those observed in experiments shown in Fig. 4.

There has been a major change in the use of PE (instead of ephedrine) in spinal anaesthesia for the treatment of hypotension during surgery [56]. PE is sometimes preferred because of its selective \( \alpha_1 \)-action. The NA-releasing property of PE described in the present study and its off-target effects described in several studies may be risk factors that compromise host defence and increase susceptibility to infection, which are strongly related to its effects on \( \beta \)-adrenoceptors expressed on immune cells [57], resulting in an immunosuppressive state [19, 58].

In summary, although the various effects of PE have been narrowly constrained to \( \alpha_1 \)-adrenoceptors in existing textbook data, we conclude that PE is not a selective, directly-acting \( \alpha_1 \)-adrenoceptor agonist. Rather, its pharmacological effects on \( \alpha_1 \)-adrenoceptors and several unexpected side effects that are characteristic of \( \alpha_2 \)- and \( \beta \)-adrenoceptor activation observed in pharmacological experiments and clinical practice are due to the cytoplasmic release of NA mediated by the off-target effect of PE on NAT (Fig. 9). However, among the compounds studied with respect to \( \alpha_1 \)-adrenoceptors, significant deviation between their functional and binding affinities was also shown [40, 59, 60] calling attention that homogenate radioligand binding studies in recombinant systems may present a bias and may not predict the real pharmacological profiles of the drug studied [40]. Therefore, these type of studies should be translated to therapeutically relevant native tissues equipped with receptors [40] including native-like molecular environment [61], and more importantly using intact animals. In addition, in studies in which PE used as standard reference of \( \alpha_1 \)-agonists, and carried out in tissues containing some source of NA, that is the endogenous native agonist of PE, at potency and efficacy estimation its NA-releasing capacity should be taken into account.
Acknowledgements This study was supported by the Eötvös Lóránd Research Network and NRDI fund (TKP2021-EGA-25). The authors also thank Ms. Judit Csek and Ms. Orsi Gere for their administrative work and Ms. Anita Bagó (Institute of Experimental Medicine) for her technical assistance.

Author Contributions ESV MD, PhD, HonFBPhS and MA-K PharmD, PhD performed the study design, scientific interpretation and writing of the manuscript with BS. DÁK and ARG planned and performed the experiments and analysed the data.

Funding Open access funding provided by Semmelweis University. This work was supported by Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the Neurology Thematic Programme of Semmelweis University (TKP 2021 EGA-25). E. Sylvester Vizi has received research support from the Eötvös Lóránd Research Network.

Data Availability The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors declare no conflicts of interest.

Ethical Approval The experiments followed the guidelines of the Ethical Board of Semmelweis University (EC Directive 2010/63/EU). The Semmelweis University Regional and the Institutional Committee of Science and Research Ethics committees approved the experimental protocol (No. 116/2015).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153(3):586–600
2. Minneman KP et al (1994) Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol 46(5):929–936
3. Hieble JP et al (1995) International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 47(2):267–470
4. Vizi ES (1986) Compounds acting on alpha 1- and alpha 2-adrenoceptors: agonists and antagonists. Med Res Rev 6(4):431–449
5. Goodman & Gilman’s (2017) The pharmacological basis of therapeutics, 13th edn. McGraw Hill, New York
6. Rang RFGHYKLDMH (2018) Rang & Dale’s pharmacology, 9th edn. Elsevier, Amsterdam
7. da Silva Junior ED et al (2017) Factors influencing biased agonism in recombinant cells expressing the human α1A-adrenoceptor. Br J Pharmacol 174(14):2318–2333
8. Isaiilova M et al (2002) Binding and functional affinity of saropogrelate, its metabolite M-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology 65(2):69–73
9. Yoshiki H et al (2013) Agonist pharmacology at recombinant alpha1A—and alpha1L-adrenoceptors and in lower urinary tract alpha1-adrenoceptors. Br J Pharmacol 170(6):1242–1252
10. Xu C et al (2019) Preventive intramuscular phenylephrine in elective cesarean section under spinal anesthesia: a randomized controlled trial. Int J Surg 62:5–11

Fig. 9 Mode of action of PE. Role of NAT in vesicular (A) and cytoplasmic (B) release of NA. A NAT controls the temporal and spatial action of released NA by taking back from the extracellular space and NA reused for refilling vesicles. B PE is the substrate of NAT and by means of NAT transported into the cytoplasm together with two Na+ and one Cl− ions [45] followed by a counter movement of NA into the extracellular space where it acts on α1-adrenoceptors. The effect is large in extracellular concentrations, it does not require axonal activity and Ca2+ influx, and hence it is termed non-exocytotic release from noradrenergic boutons without making synaptic contacts [62]. The smooth muscle cells are equipped with highly sensitive α1-adrenoceptors, this type of non-synaptic receptors are the target of drug treatment [63]. Nisoxetine, a selective NAT inhibitor, inhibits the uptake of NA released in response to action potential (see A) or prevents PE from entering the nerve terminal and the subsequent NA release (B)
11. Starke K (1972) Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn Schmiedebers Arch Pharmacol 274(1):18–45

12. Starke K, Endo T, Taube HD (1975) Relative pre- and postsynaptic potencies of alpha-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn Schmiedebers Arch Pharmacol 291(1):55–78

13. Hopwood SE, Stanford JA (2001) Noradrenergic modulation of serotonin release in rat dorsal and median raphe nuclei via alpha(1) and alpha(2A) adrenoceptors. Neuropharmacology 41(4):433–442

14. Paton WD, Vizi ES (1969) The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip. Br J Pharmacol 35(1):10–28

15. Flavahan NA, McGrath JC (1981) The role of MAO-A and MAO-B in the metabolic degradation of noradrenaline in human arteries. J Pharmacol Exp Ther 188(3):640–653

16. Wagner J, Reinhardt D (1974) Characterization of the adrenoceptors mediating the positive ino- and chronotropic effect of phenylephrine on isolated atra from guinea pigs and rabbits by means of adrenolytic drugs. Naunyn Schmiedebers Arch Pharmacol 282(3):295–306

17. Chess-Williams RG, Williamson KL, Broadley KJ (1990) Whether phenylephrine exerts inotropic effects through alpha- or beta-adrenoceptors depends upon the relative receptor populations. Fundam Clin Pharmacol 4(1):25–37

18. Torp KD et al (2001) beta-Receptor agonist activity of phenylephrine in the human forearm. J Appl Physiol 90(5):1855–1859

19. Stoilk RF et al (2021) Phenylephrine impairs host defence mechanisms to infection: a combined laboratory study in mice and translational human study. Br J Anaesth 126(3):652–664

20. Stavert B et al (2015) Cardiovascular adverse effects of phenylephrine eyedrops: a systematic review and meta-analysis. JAMA Ophthalmol 133(6):647–652

21. Luchelli-Fortis MA, Langer SZ (1974) Reserpine-induced depletion of the norepinephrine stores: is it a reliable criterion for the classification of the mechanism of action of sympathomimetic amines? J Pharmacol Exp Ther 188(3):640–653

22. Schumann HJ, Endo M, Wagner J (1974) Positive inotropic effects of phenylephrine in the isolated rabbit papillary muscle mediated both by alpha- and beta-adrenoceptors. Naunyn Schmiedebers Arch Pharmacol 284(2):133–148

23. Vizi ES et al (1985) External Ca-independent release of norepinephrine by sympathomimetics and its role in negative feedback modulation. Proc Natl Acad Sci USA 82(24):8775–8779

24. Vizi ES et al (1986) Release of [3H]norepinephrine by alpha 1-adrenoceptor agonists. Neurochem Res 11(1):71–84

25. Sylvestor Vizi E et al (1986) Release of [3H]norepinephrine by alpha 1-adrenoceptor agonists. Neurochem Res 11(1):71–84

26. Marshall I et al (1978) alpha-adrenoceptors in the mouse vas deferens and their effects on its response to electrical stimulation. Br J Pharmacol 62(1):147–151

27. Lacko E et al (2012) A novel micro-opioid receptor ligand with high in vitro and in vivo agonist efficacy. Curr Med Chem 19(27):4699–4707

28. Figueiredo IV et al (1998) The role of MAO-A and MAO-B in the metabolic degradation of noradrenaline in human arteries. J Auton Pharmacol 18(2):123–128

29. Vizi ES, Burnstock G (1988) Origin of ATP release in the rat vas deferens: concomitant measurement of [3H]norepinephrine and [14C]ATP. Eur J Pharmacol 158(1–2):69–77

30. Gerewich Z et al (2001) Analysis of high intracellular [Na+]-induced release of [3H]norepinephrine in rat hippocampal slices. Neuroscience 104(3):761–768

31. Vizi ES, Sperlagh B, Baranyi M (1992) Evidence that ATP released from the postsynaptic site by noradrenaline, is involved in mechanical responses of guinea-pig vas deferens: cascade transmission. Neuroscience 50(2):455–465

32. Ambache N, Zar MA (1971) Some physiological and pharmacological characteristics of the motor transmission in the guinea-pig vas deferens. J Physiol 212(2):15P–16P

33. Kennedy C (2015) ATP as a cotransmitter in the autonomic nervous system. Auton Neurosci 191:2–15

34. Sudhof TC (1995) Vesamicol as a cotransmitter ATP and noradrenaline. Eur J Pharmacol 278(3):295–306

35. Yaffe D et al (2016) Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis. Proc Natl Acad Sci USA 113(47):E7390–E7398

36. Westfall DP, Fedan JS (1975) The effect of pretreatment with 6-hydroxydopamine on the norepinephrine concentration and sensitivity of the rat vas deferens. Eur J Pharmacol 33(2):413–417

37. Lee TJ, Westfall DP, Fleming WW (1975) The correlation between spontaneous contractions and postjunctional supersensitivity of the smooth muscle of the rat vas deferens. J Pharmacol Exp Ther 192(1):136–148

38. Blue DR Jr et al (1995) Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat. Br J Pharmacol 115(2):283–294

39. Knepper SM et al (1995) A6-1603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther 274(1):97–103

40. Ford AP et al (1997) Pharmacological pleiotropism of the human recombinant alpha 1A-adrenoceptor: implications for alpha 1-adrenoceptor classification. Br J Pharmacol 121(6):1127–1135

41. Muramatsu I et al (1998) Alpha1-adrenoceptor subtypes and two receptor systems in vascular tissues. Life Sci 62(17–18):1461–1465

42. Knepper SM et al (1995) Alpha 1-adrenoceptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther 274(1):97–103

43. Szatowski M, Attwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17(9):359–365

44. Roman V et al (2021) Contribution of analog signaling to neurotransmitter interactions and behavior: role of transporter-mediated nonquantal dopamine release. Physiol Rep 9(21):e15088

45. Sitte HH, Freisnuth M (2015) Amphetamine, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36(1):41–50

46. Zsilla G et al (2018) 3,4-Methylenedioxymethamphetamine, mephedrone, and beta-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake. Eur J Pharmacol 837:72–80

47. Ambache N, Zar MA (1971) Some physiological and pharmacological characteristics of the motor transmission in the guinea-pig vas deferens. J Physiol 212(2):15P–16P

48. Trendelenburg U, Maxwell RA, Pluchino S (1970) Methoxamine, an alpha 1-adrenoceptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther 274(1):97–103

49. Torp KD et al (2001) Beta-Receptor agonist activity of phenylephrine in the human forearm. J Appl Physiol 90(5):1855–1859

50. Vizi ES et al (1986) Release of [3H]norepinephrine by alpha 1-adrenoceptor agonists. Neurochem Res 11(1):71–84

51. Sylvestor Vizi E et al (1986) Release of [3H]norepinephrine by alpha 1-adrenoceptor agonists. Neurochem Res 11(1):71–84

52. Marshall I et al (1978) alpha-adrenoceptors in the mouse vas deferens and their effects on its response to electrical stimulation. Br J Pharmacol 62(1):147–151

53. Lacko E et al (2012) A novel micro-opioid receptor ligand with high in vitro and in vivo agonist efficacy. Curr Med Chem 19(27):4699–4707

54. Figueiredo IV et al (1998) The role of MAO-A and MAO-B in the metabolic degradation of noradrenaline in human arteries. J Auton Pharmacol 18(2):123–128

55. Vizi ES, Burnstock G (1988) Origin of ATP release in the rat vas deferens: concomitant measurement of [3H]norepinephrine and [14C]ATP. Eur J Pharmacol 158(1–2):69–77

56. Gerewich Z et al (2001) Analysis of high intracellular [Na+] induced release of [3H]norepinephrine in rat hippocampal slices. Neuroscience 104(3):761–768

57. Vizi ES, Sperlagh B, Baranyi M (1992) Evidence that ATP released from the postsynaptic site by noradrenaline, is involved in mechanical responses of guinea-pig vas deferens: cascade transmission. Neuroscience 50(2):455–465
51. Sperlagh B et al (1998) Co-release of endogenous ATP and [3H] noradrenaline from rat hypothalamic slices: origin and modulation by alpha2-adrenoceptors. Neuroscience 82(2):511–520
52. Westfall TD, Kennedy C, Sneddon P (1996) Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156. Br J Pharmacol 117(5):867–872
53. Hillarp NA (1958) The release of catechol amines from the amine containing granules of the adrenal medulla. Acta Physiol Scand 43(3–4):292–302
54. Smith AD (1972) Subcellular localisation of noradrenaline in sympathetic neurons. Pharmacol Rev 24(3):435–457
55. Brock JA, Cunnane TC (1999) Effects of Ca2+ concentration and Ca2+ channel blockers on noradrenaline release and purinergic neuroeffector transmission in rat tail artery. Br J Pharmacol 126(1):11–18
56. Heesen M, Girard T, Klimek M (2021) Noradrenaline—at best it is not worse. A comparison with phenylephrine in women undergoing spinal anaesthesia for caesarean section. Anaesthesia 76(6):743–747
57. Hasko G, Szabo C (1998) Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system. Biochem Pharmacol 56(9):1079–1087
58. Elenkov IJ et al (2000) The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52(4):595–638
59. Yoshio R et al (2001) Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol 86(2):189–195
60. da Silva Junior ED et al (2017) Factors influencing biased agonism in recombinant cells expressing the human alpha1A-adrenoceptor. Br J Pharmacol 174(14):2318–2333
61. Luttrell LM, Maudsley S, Bohn LM (2015) Fulfilling the promise of “Biased” g protein-coupled receptor agonism. Mol Pharmacol 88(3):579–588
62. Bennett MR et al (1995) Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res 77(6):1136–1142
63. Vizi ES et al (2010) Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br J Pharmacol 160(4):785–809

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.